In just days, a number of generic versions of Lipitor will hit pharmacy shelves. Pfizer’s 180-day generic exclusivity agreement for the medication expires at the end of the month. That will bring a host of new generic alternatives, and potential confusion, to more than 3 million Americans looking to control their cholesterol and reduce the cost of their drug therapies.
Clark Kebodeaux, PharmD, assistant professor pharmacy practice at St. Louis College of Pharmacy, deals with this issue every day when he’s practicing at Walgreens in St. Louis.
He will answer some common questions including:
- Will the price of Lipitor come down?
- Will the new generic alternatives work as well as Lipitor?
- Does the generic medication affect me differently?
- Do the inactive ingredients in the medication have any effect on patients?
- Are there cases where the brand name works better than the generic?
- Questions patients should ask their pharmacist or doctor about switching to generic.
Lipitor is the best-selling prescription drug of all time, and most prescribed brand-name drug in America. Every day about 3.5 million Americans take Lipitor.
Source: St. Louis College of Pharmacy






May 16th, 2012
John Buck
This article is the final installment in a three-part series on the National Commission on the Certification of Physician Assistants’ (NCCPA) enforcement of the Code of Conduct for Certified and Certifying PAs. In the first, I outlined the organization’s disciplinary review process, providing background on the disciplinary policy’s development and how cases are handled. In my second column, I shared insights into the two most common triggers of the disciplinary review process: (1) the diversion and self-administration of Controlled Dangerous Substances and (2) other abuses of prescribing privileges.









